Investors betting on the Trump trade may be missing some real risks
Wall Street investors, spurred on by Trump's pro-business agenda, could be ignoring real risks posed by the president.
Nvidia, Smucker, Muni Bonds, and 31 Other Investment Ideas From Our Roundtable Pros
Stocks are pricey—but there are values to be had. Learn more about our panelists’ picks in this week’s Roundtable installment.
Yahoo Finance11d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
While Novo Nordisk's Ozempic is the most mainstream GLP-1 medication, Eli Lilly (NYSE: LLY) has two blockbuster weight loss drugs of its own: Mounjaro and Zepbound. Mounjaro and Zepbound are by ...
The Motley Fool11d
Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
This is an enormous opportunity, and Lilly's clinical pipeline looks well positioned. Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now ...
MedCity News22d
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
Only in the crazy sector of metabolic medicines can 32% revenue growth be considered a disappointment. That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the ...
MarketWatch16d
Mounjaro and Zepbound sales disappoint, and Eli Lilly’s stock is dropping
Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...